Assessment of PD‐L1 expression and tumor‐infiltrating lymphocytes (TILs) across molecular subtypes of triple‐negative breast cancer

This publication has 8 references indexed in Scilit:

• PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies
  Breast Cancer Research and Treatment, 2020
• Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet Oncology, 2020
• Expression of PD-L1 in primary breast carcinoma and lymph node metastases
  Surgical and Experimental Pathology, 2019
• PD-L1 in breast cancer: comparative analysis of 3 different antibodies
  Human Pathology, 2018
• Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
  Oncotarget, 2017
• Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers
  Oncology Letters, 2016
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
  Annals of Oncology, 2014
• Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
  Journal of Clinical Oncology, 2013